de Marinis F - Search Results

1

Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations.

Passaro A, Attili I, Rappa A, Vacirca D, Ranghiero A, Fumagalli C, Guarize J, Spaggiari L, de Marinis F, Barberis M, Guerini-Rocco E. Passaro A, et al. Among authors: de marinis f. Cancers (Basel). 2021 Apr 30;13(9):2172. doi: 10.3390/cancers13092172. Cancers (Basel). 2021. PMID: 33946519 Free PMC article.

2

Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?

Passaro A, Cortesi E, de Marinis F. Passaro A, et al. Among authors: de marinis f. Expert Rev Anticancer Ther. 2011 Oct;11(10):1587-97. doi: 10.1586/era.11.120. Expert Rev Anticancer Ther. 2011. PMID: 21999132 Review.

3

Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials.

Passaro A, Gori B, de Marinis F. Passaro A, et al. Among authors: de marinis f. J Thorac Dis. 2013 Aug;5(4):383-4. doi: 10.3978/j.issn.2072-1439.2013.07.32. J Thorac Dis. 2013. PMID: 23991291 Free PMC article. No abstract available.

4

Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer.

de Marinis F, Passaro A, Clarke S. de Marinis F, et al. Lung Cancer. 2013 Dec;82(3):511. doi: 10.1016/j.lungcan.2013.09.003. Epub 2013 Sep 12. Lung Cancer. 2013. PMID: 24080011 No abstract available.

5

Afatinib-related nonhematologic adverse events: is common evaluation enough for now?

de Marinis F, Passaro A. de Marinis F, et al. J Clin Oncol. 2014 Mar 10;32(8):864-5. doi: 10.1200/JCO.2013.52.4538. Epub 2014 Feb 3. J Clin Oncol. 2014. PMID: 24493732 No abstract available.

6

Afatinib in NSCLC harbouring EGFR mutations.

de Marinis F, Catania C, Passaro A. de Marinis F, et al. Lancet Oncol. 2014 Apr;15(4):e148-9. doi: 10.1016/S1470-2045(13)70402-9. Lancet Oncol. 2014. PMID: 24694632 No abstract available.

7

Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies.

D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A, de Marinis F. D'Antonio C, et al. Among authors: de marinis f. Ther Adv Med Oncol. 2014 May;6(3):101-14. doi: 10.1177/1758834014521110. Ther Adv Med Oncol. 2014. PMID: 24790650 Free PMC article. Review.

8

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E.

Catania C, Conforti F, Spitaleri G, Barberis M, Preda L, Noberasco C, Lazzari C, Toffalorio F, de Marinis F, Manzotti M, De Pas TM. Catania C, et al. Among authors: de marinis f, de pas tm. Onco Targets Ther. 2014 May 8;7:697-702. doi: 10.2147/OTT.S58902. eCollection 2014. Onco Targets Ther. 2014. PMID: 24855380 Free PMC article.

9

management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.

Passaro A, Di Maio M, Del Signore E, Gori B, de Marinis F. Passaro A, et al. Among authors: de marinis f. Clin Lung Cancer. 2014 Jul;15(4):307-12. doi: 10.1016/j.cllc.2014.04.006. Epub 2014 May 12. Clin Lung Cancer. 2014. PMID: 24954231

10

Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors.

Toffalorio F, de Marinis F, Conforti F, Spitaleri G, Catania C, Noberasco C, Lazzari C, Vecchio F, Stufano V, Barberis M, De Pas T. Toffalorio F, et al. Among authors: de marinis f, de pas t. J Thorac Oncol. 2015 Feb;10(2):392-6. doi: 10.1097/JTO.0000000000000355. J Thorac Oncol. 2015. PMID: 25611230 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

381 results

Search Page

Filters